Results 51 to 60 of about 1,620,706 (306)

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones   +23 more
wiley   +1 more source

Expression proteomics reveals protein targets and highlights mechanisms of action of small molecule drugs

, 2014
Phenomenological screening of small molecule libraries for anticancer activity yields potentially interesting candidate molecules, with a bottleneck in the determination of drug targets and the mechanism of anticancer action.
Chernobrovkin, Alexey, Vicente, Consuelo Marin, Visa, Neus, Zubarev, Roman A.   +3 more
core   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

PPARα regulates YAP protein levels and activity by affecting its ubiquitination modification

BMC Biology
Background Peroxisome proliferator-activated receptor α (PPARα) plays a crucial role in liver physiological and pathological processes. Yes-associated protein (YAP) is a key effector in regulating cell growth and organ size.
Wenhong Zhou, Shuaishuai Zhang, Yao Chen, Ziqi Chen, Guofang Bi, Manlan Guo, Xiaowen Jiang, Xiao Yang, Jianhong Fang, Linhu Ye, Shicheng Fan, Huichang Bi   +11 more
doaj   +1 more source

Antihyperuricemic effect of mangiferin aglycon derivative J99745 by inhibiting xanthine oxidase activity and urate transporter 1 expression in mice

Acta Pharmaceutica Sinica B, 2018
A mangiferin aglycon derivative J99745 has been identified as a potent xanthine oxidase (XOD) inhibitor by previous in vitro study. This study aimed to evaluate the hypouricemic effects of J99745 in experimental hyperuricemia mice, and explore the ...
Zhizhen Qin, Shoubao Wang, Yihuang Lin, Ying Zhao, Shengqian Yang, Junke Song, Tao Xie, Jinlong Tian, Song Wu, Guanhua Du   +9 more
doaj   +1 more source

Comparison of a checklist for clinical signs of impairment and detection of drugs in saliva [PDF]

, 2010
Objectives: In Belgium and some other countries, the police performs on-site drug screening when a driver is suspected of being drug impaired, since the test procedure is time consuming and the screening devices are relatively expensive. The objective of
Goessaert, An-Sofie, Legrand, Sara-Ann, Veramme, Jolien, Verstraete, Alain   +3 more
core  

The efficiency of multi-target drugs: the network approach might help drug design

, 2005
Despite considerable progress in genome- and proteome-based high-throughput screening methods and rational drug design, the number of successful single target drugs did not increase appreciably during the past decade.
Agoston, Vilmos, Csermely, Peter, Pongor, Sandor   +2 more
core   +1 more source

Lung tumorspheres as a drug screening platform against cancer stem cells [PDF]

, 2019
Treatment resistance and metastasis are linked to cancer stem cells (CSCs). This population represents a promising target, but remains unexplored in lung cancer.
Amado, H., Blasco, Ana, Calabuig, Silvia, Camps, C., Durendez-Saez, Elena, Escorihuela, Eva, Herreros Pomares, Alejandro, Jantus Lewintre, Eloisa, Murga, Juan, Navarro, A., Sampedro, C., Torres, Susana, Zhang, F.   +12 more
core   +1 more source

Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing [PDF]

, 2019
Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery.
Baldwin, Nicole E., Chan, Jinyan, Gu, Jinghua, Turner, Jacob A., Wang, Xuan   +4 more
core   +1 more source

A programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for vedolizumab clinical trials [PDF]

, 2018
Introduction Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory ...
Berger, Joseph R, Clifford, David B, Fox, Irving, Lev, Michael H, Major, Eugene, McAuliffe, Megan, Milch, Catherine, Parikh, Asit, Patti, Mark, Provenzale, James M, Sankoh, Serap, Shick, Jesse, Stephens, Kristin   +12 more
core   +3 more sources